Αρχική World News Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in Death

Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in Death

The researchers from the Massachusetts General Hospital in Boston, MA, US led by assistant professor Meghan Sise, published on 18 May 2021 in the Annals of Oncology the results of a large analysis examining whether the immune checkpoint inhibitors (ICIs) induced thyroiditis is associated with prolonged survival in a retrospective cohort of adults treated with ICIs between 2010 and 2019. The study team showed a 20% reduction in the adjusted hazard ratio (aHR) for death in patients who developed ICI induced thyroiditis. The association between thyroiditis and overall survival (OS) varied by tumour type, but was strongest in patients with lung cancer, possibly related to the shared developmental origin of thyroid and lung epithelia.

The authors wrote in the background that it has been hypothesised that immune-related adverse events (irAEs) are a biomarker for treatment effect and a positive prognostic indicator in patients receiving ICIs. The ICI induced thyroiditis is a common irAE that has been associated with improved survival. They investigated whether the prolonged survival associated with ICI induced thyroiditis was a result of immortal time bias.

The researchers identified 9,419 patients receiving ICIs, but after exclusions, 6,596 were included in this analysis. Mean age was 64 years, 57% were male and 89% white, non-Hispanic. Patients were followed for a median of 9.6 months. Thyroiditis was developed in 1,155 patients (17%). Median time to thyroiditis was 3.1 months.

Multivariable models were adjusted for age, sex, race, cancer type, ICI class, pre-existing rheumatologic disease, and Charlson comorbidity score. The ICI induced thyroiditis was independently associated with a large improvement in OS in the time-independent model (aHR 0.47, 95% confidence interval [CI] 0.44-0.53, p < 0.001). The association with improved survival remained consistent, albeit with a lower effect estimate with time-varying Cox models (aHR 0.80, 95% CI 0.71-0.89, p < 0.001).

In the survival analysis, without applying a conditional landmark, thyroiditis was associated with a large reduction in death (HR 0.44 p <0.001). When a 6-month landmark was applied, a weaker, but statistically significant improvement in OS was found, HR for death 0.76 (95% CI 0.65–0.88, p < 0.001). Applying a 3-month landmark yielded a very similar result of HR 0.78 (95% CI 0.67–0.92, p = 0.002).

A 6-month landmark analysis was used to determine the association between thyroid dysfunction and OS in each cancer type. Patients with lung cancer demonstrated the strongest relationship between thyroiditis and OS (HR for death 0.56, 95% CI 0.40-0.79, p < 0.001). The relationship was least in breast, melanoma and genitourinary tumours.

The authors wrote that their study demonstrates the large effect of immortal time bias. Future studies with large cohorts are needed to examine the association of other irAEs with survival.

Reference

Street S, Chute D, Strohbehn I, et al. The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6,596 patients. Annals of Oncology; Published online 18 May 2021. DOI: https://doi.org/10.1016/j.annonc.2021.05.357

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...